抗病毒药物市场－全球产业规模、份额、趋势、机会和预测，按类型、药物类别、配销通路、应用、地区和竞争格局划分，2020-2030年预测

2024年全球抗病毒药物市场规模为771亿美元，预计2030年将以3.89%的复合年增长率成长至969.4亿美元。抗病毒药物是用来抑制病毒在宿主体内复製和增殖的药物，进而治疗或预防爱滋病、肝炎和流感等病毒感染。该市场的成长主要受全球病毒性疾病发生率上升、药物研发投入巨资以及积极进行的公共卫生感染控制活动等因素所驱动。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球抗病毒药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型（品牌药、仿製药）
  • 依药物类别（DNA聚合酶抑制剂、逆转录酶抑制剂、蛋白酶抑制剂、神经氨酸酶抑制剂、其他）
  • 按应用（爱滋病、肝炎、疱疹、流感、其他）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美抗病毒药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲抗病毒药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区抗病毒药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲抗病毒药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲抗病毒药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球抗病毒药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• F. Hoffmann-La Roche Ltd
• GSK plc.
• AbbVie, Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Aurobindo Pharma
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Anti-Viral Drugs Market, valued at USD 77.10 Billion in 2024, is projected to experience a CAGR of 3.89% to reach USD 96.94 Billion by 2030. Antiviral drugs are pharmaceutical agents developed to inhibit viral replication and proliferation within a host, thereby treating or preventing viral infections such as HIV, hepatitis, and influenza. The market's growth is primarily driven by the escalating global incidence of viral diseases, substantial investments in pharmaceutical research and development, and proactive public health campaigns for infection control.

Key Market Drivers

The increasing global prevalence of viral infections stands as a significant driver for the antiviral drugs market, creating an enduring demand for effective therapeutic solutions. The continuous emergence of new viral strains and the persistent burden of established pathogens pose substantial public health challenges, from seasonal outbreaks to widespread epidemics. For example, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) in its 2023 Global AIDS Update, an estimated 1.3 million people worldwide became newly infected with HIV in 2022. This ongoing incidence necessitates the development of advanced antiviral treatments to manage and prevent disease progression, thereby directly influencing market demand for these crucial pharmaceutical products.

Key Market Challenges

The rapid evolution of viral resistance to existing therapeutic agents presents a significant obstacle to the sustained growth of the global anti-viral drugs market. As viruses mutate and develop resistance, the efficacy of current treatments diminishes, necessitating the continuous development of novel compounds. This ongoing requirement for new pharmaceutical agents directly impedes market expansion by escalating development costs and increasing regulatory complexities.

Key Market Trends

The growing adoption of AI-driven drug discovery for antivirals represents a significant shift in pharmaceutical research, aiming to accelerate the identification and development of novel compounds. This trend leverages advanced computational techniques to analyze vast biological datasets, predict molecular properties, and optimize drug designs, thereby streamlining the notoriously lengthy and expensive drug development process. According to a survey from cloud vendor Rackspace Technology and Dell/VMware conducted in October 2023, 67% of pharmaceutical companies planned to increase their IT investments, including AI, over the subsequent 12 months, highlighting this strategic pivot.

Key Market Players

• F. Hoffmann-La Roche Ltd
• GSK plc.
• AbbVie, Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Aurobindo Pharma
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the Global Anti-Viral Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Viral Drugs Market, By Type:

• Branded
• Generics

Anti-Viral Drugs Market, By Drug Class:

• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others

Anti-Viral Drugs Market, By Application:

• HIV
• Hepatitis
• Herpes
• Influenza
• Others

Anti-Viral Drugs Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Anti-Viral Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anti-Viral Drugs Market.

Available Customizations:

Global Anti-Viral Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Viral Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Branded, Generics)
  • 5.2.2. By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others)
  • 5.2.3. By Application (HIV, Hepatitis, Herpes, Influenza, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Anti-Viral Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Application
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Anti-Viral Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Anti-Viral Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Anti-Viral Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Distribution Channel

7. Europe Anti-Viral Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Application
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Anti-Viral Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Anti-Viral Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Anti-Viral Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Anti-Viral Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Anti-Viral Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Anti-Viral Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Application
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Anti-Viral Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Anti-Viral Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Anti-Viral Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Anti-Viral Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Anti-Viral Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Anti-Viral Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Application
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Anti-Viral Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Anti-Viral Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Anti-Viral Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Distribution Channel

10. South America Anti-Viral Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Application
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Anti-Viral Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Anti-Viral Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Anti-Viral Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Anti-Viral Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GSK plc.
• 15.3. AbbVie, Inc.
• 15.4. Merck & Co., Inc.
• 15.5. Johnson & Johnson Services, Inc.
• 15.6. Bristol-Myers Squibb Company
• 15.7. Aurobindo Pharma
• 15.8. Cipla Limited
• 15.9. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer